[Anti-HBs-F(ab)'2 to the seroconversion of HBsAg carriers].
The exogenous anti-HBs-F(ab)'2 was given to the HBsAg carriers for the study of its effect of seroconversion in vivo. 30 HBsAg carriers, with a duration of 2-15 years (HBeAg positive 18 and anti-HBe positive 12) were studied after intramuscular infection of anti-HBs-F(ab)'2. In the HBeAg group, the cut off value of HBeAg decreased significantly (P < 0.01) in 18 carriers, of which 6 seroconversed to anti-HBe, all the HBe-Ag carriers had a high S/N ratio of anti-HBs-anti-Id (RIA) but after 12-week treatment the ratio decreased significantly (P < 0.01). Six of 18 HBV DNA positive carriers conversed to negative (33%) and 8 of 13 DNA-P positive conversed to negative (61%). 12 anti-HBe positive carriers showed no seroconversion.
An
P
P
Institute of Liver Disease of PLA, Beijing.
D000293:Adolescent; D000328:Adult; D002353:Carrier State / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000628:therapy*; D006510:Hepatitis B Antibodies / Q000627:therapeutic use*; D006514:Hepatitis B Surface Antigens / Q000276:immunology*; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007140:Immunoglobulin Fab Fragments